Covid 19

Good News! Oxford Vaccine Shows Positive Results Against Coronavirus, Increases Antibodies and T-Cells As Well


According to Oxford University, serious side effects were not seen during the vaccine trial. Only minor problems such as fatigue, headache, chills and body aches occurred.

The first clinical trial of a Coronavirus vaccine being made at Oxford University has yielded good results. According to a report published in the medical journal The Lancet on Monday, the vaccine is completely safe and effective. Among all the vaccine candidates, the Oxford-AstraZeneca vaccine has come up as frontrunner.

The tweet from Oxford University also said that this vaccine named AZD1222 has given good immune response. The team involved in the vaccine trial and the Oxford Monitoring Group did not see any concern about safety in this vaccine and this has led to a strong response.

Describing the vaccine, The Lancet’s Editor-in-Chief Richard Horton has used three special medical terms – safe, well-tolerated and immunogenic. Horton has congratulated the vaccine team’s chief scientist, Padro Follegaty, and said that these results are very encouraging.

You can read the 13-page report published in The Lancet about this vaccine by clicking on this link –

Double Protection Against Coronavirus

Two days ago, a July 17 report suggested that this vaccine could offer double protection against coronaviruses. According to the Daily Telegraph, the immune response in volunteers was significantly better after the vaccine was given in the first phase of the trial. Their blood samples were tested. The report revealed that they also contained antibodies against the corona and killer T-cells.

After this, on Sunday, 19 July, Richard was the first to tweet that the results of the Oxford vaccine will be announced on Monday. Horton tweeted, “Yesterday. Vaccine. Just waiting, I am saying. ”Since then, this tweet was being discussed everywhere and everyone was waiting for the trial result.

Claims to make more antibodies than Coronavirus Survivor

AstraZeneca, a pharma company producing Coronavirus vaccines with Oxford University, has claimed in the New England Journal of Medicine that the vaccines given during the trial contained more antibodies than the corona Survivor. Dr. Anthony Fossey, director of the National Institute of Allergy and Infectious Diseases, says the results are good, hoping that the vaccine will succeed.

The trial did not show major side effects

According to Oxford University, serious side effects were not seen during the trial. Only minor problems such as fatigue, headache, chills and body aches occurred. Where there was an injection, there was pain, but this was seen only in cases of overdose.

First phase trial was held in April

The first phase trial was conducted by Oxford University in April. According to Health Minister Matt Hencock, the team is constantly working to prepare the Coronavirus vaccine, which may be available anytime this year. If not, it is expected to come in 2021.

David Carpenter, chairman of the Berkshire Research Ethics Committee, which approves the vaccine trial, says that we are constantly working with scientists and making every necessary change. We are on the right track in preparing the vaccine.

Vaccine may be available by September

According to Carpenter, researchers can target to give vaccines to hospitals, healthcare professionals, because they are more at risk of spreading the infection. The date of when the vaccine will be available cannot be given, however, tentatively it can be available by September.

No observation regarding long-term immunity

According to the report, a source says that it has not yet been proven that Oxford’s vaccine ChAdOx1 nCoV-19 will give immunity for a long time. However, it increases the number of both antibodies and T-cells in the body. Combination of these two things is necessary to keep a person safe. Everything has been good so far, but the road ahead is very important and long.

Target to deliver 400 million doses free by the end of 2020

Pharma company AstraZeneca has joined hands with Europe’s Inclusive Vaccines Alliance to produce 400 million doses of the vaccine. The target for vaccine preparation by the end of 2020 has been set. 400 million doses of vaccine will be made available free of cost.

How was Oxford Vaccine made?

The vaccine ChAdOx1 nCoV-19 is made using a weak version of a cold virus (adenovirus). This virus is an infection in chimpanzees. It has been genetically modified to use it in vaccine, so that it can produce immunity in humans against similar viruses.

Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.

Related posts